Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study
To determine the impact of Neoadjuvant chemotherapy on surgical debulking rate, overall and disease-free survival and quality of life (QOL) in patients with advanced EOC.
Ovarian Carcinoma
OTHER: timing of surgery|OTHER: timing of surgery
to compare the optimal debulking rate in primary surgery group and neoadjuvant chemotherapy group, post surgery
post operative morbidity, 3 weeks post op
To determine the impact of Neoadjuvant chemotherapy on surgical debulking rate, overall and disease-free survival and quality of life (QOL) in patients with advanced EOC.